USA flag logo/image

An Official Website of the United States Government

Refanalin for lung preservation and transplantation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85787
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HL080806
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Refanalin for lung preservation and transplantation
Agency: HHS
Contract: 2R44HL080806-02
Award Amount: $2,075,083.00
 

Abstract:

DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting early graft function, graft viability and recipient morbidity and mortality. Marginal donor lungs, are even more susceptible to ischemia-reperfusion injury, and often fail transplantation. Scatter factor/hepatocyte growth factor has significant protective activity in the setting of pulmonary ischemia-reperfusion injury and additionally, favors pulmonary epithelial repair and regeneration. However its clinical use is limited by the logistical difficulties associated with its administration. During our Phase I program, we have identified Refanalin, an organic small molecule scatter factor/hepatocyte growth factor mimetic that improves lung function secondary to ischemia-reperfusion injury, attenuates pulmonary epitheli al death and promotes epithelial regeneration. In a preclinical model of lung cold preservation and transplantation, Refanalin treatment reduced roentgenographic alveolar infiltration, improved pulmonary function and preserved pulmonary microarchitecture. The present Phase II makes an in-depth evaluation of Refanalin efficacy in clinically relevant models of lung transplantation. By attenuating allograft dysfunction and preventing allograft failure, Refanalin can reduce recipient morbidity and mortality. By attenuating ischemia- reperfusion injury in the marginal lung, Refanalin can salvage an otherwise discarded organ, and increase the donor pool. PUBLIC HEALTH RELEVANCE: A small molecule cytoprotective that can be added to the lung preservation solution an d administered to graft recipient has significant clinical potential in lung and other solid organ transplantation.

Principal Investigator:

Weizhong Cai
5165621140
WCAI@ANGION.COM

Business Contact:


igoldberg@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 1050 Stewart Ave. Garden City, NY 11530

EIN/Tax ID: 113430072
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No